Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Update on Phase I/II study of glofitamab monotherapy in R/R MCLПодробнее

Update on Phase I/II study of glofitamab monotherapy in R/R MCL

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCLПодробнее

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCL

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCL

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCLПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL

Glofitamab for Richter’s TransformationПодробнее

Glofitamab for Richter’s Transformation

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy data

A Phase I/II trial of glofitamab monotherapy in R/R MCLПодробнее

A Phase I/II trial of glofitamab monotherapy in R/R MCL

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCL

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & more

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

Relapsed and Refractory Diffuse Large B-Cell LymphomaПодробнее

Relapsed and Refractory Diffuse Large B-Cell Lymphoma

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformation

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapy

The emerging potential of bispecific antibodies as monotherapy & in combination for B-cell lymphomaПодробнее

The emerging potential of bispecific antibodies as monotherapy & in combination for B-cell lymphoma

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCLПодробнее

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphomaПодробнее

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphoma

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCLПодробнее

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCL